Paesmans M
Unité de Biostatistiques, Institut Jules Bordet, Bruxelles.
Rev Med Brux. 1995 Jan-Feb;16(1):6-13.
The knowledge of pretreatment factors playing a role in the evolution of a lung cancer is important for the choice of a therapeutic option in an individual patient but is also crucial when performing clinical research. The purpose of this paper is to review the prognostic parameters recognized in three distinct populations. For small cell lung cancer, disease extent and performance status are the most discriminant well known factors. Age, sex, lactic dehydrogenase serum level and mediastinal involvement provide complementary information. For non small cell lung cancer, operability status is the variable responsible for the greatest heterogeneity. TNM classification, histology, age and sex and probably knowledge of some biological values are useful data to improve accuracy in the prognosis of operable patients. For patients unresectable at diagnosis, disease extent and performance status are the most important prognostic factors to which age, sex and some biological parameters could be added.
了解在肺癌进展中起作用的预处理因素,对于个体患者治疗方案的选择很重要,在进行临床研究时也至关重要。本文旨在回顾在三个不同人群中公认的预后参数。对于小细胞肺癌,疾病范围和体能状态是最具鉴别力的已知因素。年龄、性别、乳酸脱氢酶血清水平和纵隔受累情况提供补充信息。对于非小细胞肺癌,可手术状态是导致最大异质性的变量。TNM 分类、组织学、年龄和性别以及一些生物学指标的信息可能有助于提高可手术患者预后评估的准确性。对于诊断时不可切除的患者,疾病范围和体能状态是最重要的预后因素,年龄、性别和一些生物学参数也可作为补充。